Belgium - Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the 'Company' or 'Mithra'), a company dedicated to Women's Health, confirms to Bondholders that, in accordance with the terms and conditions of the Company's EUR 125,000,000 senior unsecured convertible bonds due 2025 (ISIN: BE6325746855) (the 'Bonds'), as a result of the issuance on 23 November 2023, as part of the private placement announced on 24 August 2023, of (i) 10 million subscription rights, with a 5-year term, to subscribe for 10 million new ordinary shares at an exercise price of EUR 2.25 per share, and (ii) 10 million subscription rights, with a 18-month term, to subscribe for 10 million new ordinary shares at an exercise price of EUR 2.25 per share, pursuant to Condition 5(b), the Conversion Price of the Bonds has been adjusted from EUR 23.2370 to EUR 23.0160, effective as of 23 November 2023.

Capitalised terms not otherwise defined herein shall have the meanings given to them in the terms and conditions of the Bonds.

About Mithra

Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming women's health by offering new choices through innovation, with a particular focus on contraception and menopause.

Contact:

Tel: +32 (0)4 349 28 22

Email: info@mithra.com

Tel: +32 (0)4 353 37 00

Email: info@mithracdmo.com

(C) 2024 Electronic News Publishing, source ENP Newswire